Skip to main contentAI and Advanced
/
MARKSANS · NSEBSE SENSEX74,528.06+0.29%BSE |
NIFTY 5023,323+0.23%NSE |
NIFTY BANK56,308.1+0.45%NSE |
NIFTY IT28,626.55-1.81%NSE |
NIFTY AUTO27,240.4+0.30%NSE |
NIFTY FMCG45,498.8-0.16%NSE |
NIFTY PHARMA26,664.45+0.32%NSE |
NIFTY 50022,788.3+0.59%NSE |
MA
NSE · Equity shares · Biotechnology & Drugs-0.05 · -0.02%
Marksans Pharma MARKSANS
NSE:INR 319.65
BSE:INR 319.65
Data quality and coveragePrice, company fundamentals and optional research feeds are tracked separately.
Headline priceLast market snapshot
Company fundamentalsStale · last-known data
Research sections9 of 9 availableMissing source values remain unavailable, never zero-filled.
AI analysis and Advanced tools for MARKSANS
Analysis, reports, chat and Advanced access use the same Rusaka Markets account. The backend remains authoritative for roles, subscriptions, credits and permissions.
Snapshot
Price and key statistics
Reported and computed values remain separate; missing values are not converted to zero.
Previous closeINR 319.7
Day rangeINR 312.95 — INR 322.5
52-week rangeINR 155 — INR 349.95
Volume11.03 L
Market cap12,180.9
P/E20.9
Fundamental highlightsReported values unless marked as computed
Revenue (INR Cr)2,950.94
Net Income (INR Cr)417.9
Rev Growth (5 Year %)16.48
EPS Growth (5 Year %)9.84
P/E Ratio20.9
Book Value63.14
EPS9.26
Price/BV5.06Computed
Research path: Interpret Marksans Pharma's snapshot alongside the wider market dashboard, the financial-statement research guide and the valuation-ratios field guide.
Validated OHLC
Interactive price chart
Crosshair, OHLCV tooltip, indicators, volume, zoom and pan use the same candle API as the advanced workspace.
MARKSANSMarksans Pharma1d · INR · NSE
Loading validated candles…
Auditable calculations
Daily technical summary
Calculated from validated daily candles. Descriptive research only.
Calculating technicals…
Indicators describe price behaviour and volatility; they are not a BUY, NEUTRAL or SELL recommendation.
Company reporting
Financial statements
IND AS · INR crore
| Metric | 2026 | 2025 | 2024 |
|---|---|---|---|
| Total Liabilities Shareholders' Equity | 3,860.9 | 3,239.63 | 2,680.95 |
| Cash Equivalents | 322.36 | 217.21 | 403.28 |
| Other Liabilities Total | 5.92 | 5.92 | 4.56 |
| Accrued Expenses | 21.6 | 19.46 | 14.18 |
| Common Stock Total | 45.32 | 45.32 | 45.32 |
| Other Current Assets Total | 2 | 1.81 | 59.94 |
| Prepaid Expenses | 36.89 | 30.26 | 25.13 |
| Total Assets | 3,860.9 | 3,239.63 | 2,680.95 |
| Current Portof LT Debt/Capital Leases | 43.66 | 35.49 | 24.95 |
| Cash | 311.78 | 278.57 | Not available |
| Total Equity | 3,023.16 | 2,466.91 | 2,065.05 |
| Long Term Investments | 0.01 | 0.01 | 2.62 |
| Retained Earnings(Accumulated Deficit) | 2,977.84 | 1,749.91 | 1,425.39 |
| Total Common Shares Outstanding | 45.32 | 45.32 | 45.32 |
| Tangible Book Valueper Share Common Eq | 63.14 | 51.93 | 43.27 |
| Goodwill Net | 45.26 | 40.93 | 39.5 |
| Total Liabilities | 837.75 | 772.72 | 615.9 |
| Total Debt | 343.38 | 321.91 | 244.06 |
| Short Term Investments | 355.13 | 208.77 | 297.06 |
| Cashand Short Term Investments | 989.26 | 704.56 | 700.34 |
| Total Receivables Net | 704.9 | 609.26 | 459.14 |
| Notes Payable/Short Term Debt | 29.59 | 23.09 | 29.09 |
| Deferred Income Tax | 5.09 | 3.66 | 10.62 |
| Accounts Receivable-Trade Net | 647.88 | 542.19 | 453.18 |
| Property/Plant/Equipment Total-Net | 940.66 | 895.41 | 681.09 |
| Minority Interest | 29.52 | 22.47 | 20.85 |
| Total Current Liabilities | 527.09 | 477.34 | 389.85 |
| Total Inventory | 989.68 | 858.23 | 617.94 |
| Accounts Payable | 336.91 | 305.7 | 268.28 |
| Other Currentliabilities Total | 95.33 | 93.6 | 53.35 |
| Total Long Term Debt | 270.13 | 263.33 | 190.02 |
| Intangibles Net | 116.78 | 72.73 | 64.76 |
| Other Long Term Assets Total | 16.83 | 3.56 | 29.38 |
| Note Receivable-Long Term | 18.63 | 22.87 | 1.11 |
| Total Current Assets | 2,722.74 | 2,204.12 | 1,862.49 |
| Capital Lease Obligations | 270.13 | 263.33 | 190.02 |
| Accumulated Depreciation Total | Not available | -351.1 | -300.1 |
| Other Equity Total | Not available | 167.19 | 89.85 |
| Additional Paid-In Capital | Not available | 504.5 | 504.5 |
| Property/Plant/Equipment Total-Gross | Not available | 1,237.5 | 965.51 |
Fundamentals
Valuation and ratios
Valuation
PEG Ratio2.28
Price to Sale Ratio4.13
Growth
Debt 5Yr CAGR %54.42
Margins
Operating Margin 12m17.02
Operating Margin 5y Avg16.84
Net Profit Margin 12m14.23
Net Profit Margin 5y14.15
Yield
Dividend Yield %0.33
Risk and consensus
Source-qualified signals
Risk metrics
Overall RiskBalanced risk
Board Risk44.66
Analyst consensus
ConsensusStrong Buy
Consensus score1.50
Analyst opinions2
Strong Sell count0
Sell count0
Hold count0
Buy count1
Strong Buy count1
Provider consensus uses a 1 (Strong Buy) to 5 (Strong Sell) score. The payload does not include price targets, so none are inferred from 52-week prices or recommendation percentages.Industry context
Peer comparison
Only peers present in the company profile payload are displayed.
| Company | Price | Market cap | P/E | Research |
|---|---|---|---|---|
| Sun Pharmaceutical Industries | INR 1,944 | 4.66 L | 38.4 | — |
| Divi's Laboratories | INR 8,291.55 | 2.20 L | 73.32 | — |
| Torrent Pharmaceuticals | INR 4,965 | 1.89 L | 72.73 | — |
| Cipla | INR 1,475 | 1.19 L | 27.57 | — |
| Zydus Lifesciences | INR 1,106.25 | 1.10 L | 21.19 | — |
Shareholding
Ownership
- Promoter
- 43.87%
- FII
- 17.47%
- MF
- 4.36%
- Other
- 34.30%
Company intelligence
Latest relevant news
Source, timestamp and external destination are shown. Provider relevance scores are not available.
Marksans Pharma Ltd Falls 5.24%, BSE Healthcare index Drops 1.34% - Business StandardMarket news · 22 Jul 2026, 9:52 am
Marksans Pharma Ltd Falls 5.24%, BSE Healthcare index Drops 1.34% Business Standard
Marksans Pharma (MARKSANS) Q3 25/26 earnings summary - QuartrMarket news · 8 Jul 2026, 3:13 pm
Marksans Pharma (MARKSANS) Q3 25/26 earnings summary Quartr
Marksans Pharma Acquires Germany''s ABCnow GmbH - Rediff MoneyWizMarket news · 8 Jul 2026, 11:41 am
Marksans Pharma Acquires Germany''s ABCnow GmbH Rediff MoneyWiz
Marksans Pharma to acquire German firm ABCnow GmbH for €892,384 - scanx.tradeMarket news · 8 Jul 2026, 10:24 am
Marksans Pharma to acquire German firm ABCnow GmbH for €892,384 scanx.trade
Marksans Pharma Limited agreed to acquire Abcnow GmbH for ?0.89 million. - marketscreener.comMarket news · 7 Jul 2026, 12:30 pm
Marksans Pharma Limited agreed to acquire Abcnow GmbH for ?0.89 million. marketscreener.com
Marksans Pharma share price jumps nearly 4% on acquisition of German pharma company ABCnow Gmbh - UpstoxMarket news · 7 Jul 2026, 12:30 pm
Marksans Pharma share price jumps nearly 4% on acquisition of German pharma company ABCnow Gmbh Upstox
Corporate actions
Events
- annual General MeetingAGM
- dividendRs.0.9000 per share(90%)Final Dividend
- board MeetingsQuarterly Results
- board MeetingsAudited Results & Final Dividend
- board MeetingsQuarterly Results
- board MeetingsQuarterly Results
- board MeetingsQuarterly Results
- annual General MeetingAGM
Rusaka Markets Community
Discussion and sentiment for Marksans Pharma
Posts are linked to the canonical company record. Community BUY, NEUTRAL and SELL opinions are user-generated, moderated and separate from analyst consensus and Rusaka Markets AI.
Checking your Rusaka Markets account…
Company profile
Business information
What the company does
Marksans Pharma Limited is an India-based company, which is primarily engaged in the business of research, manufacture, marketing and sale of pharmaceutical formulations. It operates under single business segment, namely Pharmaceuticals. It operates two manufacturing facilities in Goa and maintains two research and development centers, located in Goa and in Navi Mumbai. Its product portfolio spreads various therapeutic segments of the cardiovascular system (CVS), central nervous system (CNS), antidiabetic, pain management, cough and cold, gastroenterological, and anti-allergies. Its product portfolio includes tablets (plain, enteric-coated and film-coated), hard capsules, soft gelatin capsules, oral liquids and ointments. Its consumer self-care products include pain management, upper respiratory, digestive health, vitamins, minerals and supplements (VMS) and skin care products. Its prescription - Rx therapeutic segments include CVS, CNS, oncology, anti-diabetics and anti-biotic.
Company facts
- Industry
- Biotechnology & Drugs
- Sector
- Biotechnology & Drugs
- NSE Code
- MARKSANS
- BSE Code
- 524404
Questions
Stock FAQ
What is the symbol and ISIN of Marksans Pharma?
Marksans Pharma has the symbol MARKSANS and ISIN - INE750C01026.
What is the current price of Marksans Pharma?
Marksans Pharma is currently trading at INR 319.65.
What are the year high and year low of Marksans Pharma?
Marksans Pharma has a year high of INR 349.95 and a year low of INR 155.00.
What is the market capitalization of Marksans Pharma?
Marksans Pharma has a market capitalization of INR 12,180.90 crore.
What is the P/E ratio of Marksans Pharma?
Marksans Pharma has a P/E ratio of 20.90.
What is the dividend yield of Marksans Pharma?
Marksans Pharma has a dividend yield of 0.33%.
How is the financial performance of Marksans Pharma based on revenue, net income, and EPS?
Marksans Pharma has revenue of INR 2,950.94 crore, net income of INR 417.90 crore, and EPS of INR 9.23.
What is the book value of Marksans Pharma?
Marksans Pharma has a book value of INR 63.14.
What is the debt-to-equity ratio of Marksans Pharma?
Marksans Pharma has a debt-to-equity ratio of NA.
What are the price-to-book and price-to-sales ratios of Marksans Pharma?
Marksans Pharma has a price-to-book ratio of 5.06 and a price-to-sales ratio of 4.13.
Corporate-action adjustment is provider-defined. Rusaka Markets research and computed indicators are not investment advice.